Academic Groups

Collaboration is at the heart of everything we do. We seek to engage with disease biology experts across all of our therapeutic areas of interest and provide a translational pathway towards the delivery of new treatments.

Within our Anti-Infectives Drug Discovery portfolio we work as part of international collaborations with academia, industry and product development partners, including the TB Drug Accelerator (TBDA), Malaria Drug Accelerator (MalDA), the Structure-guided Drug Discovery Coalition (SDDC) and are an Associated Partner in EU Innovative Medicines Initiative (IMI) consortia to deliver new medicines for TB and COVID.

The Innovative Targets Portfolio was established in 2009 to bridge the gap between leading academic research and commercial drug development. Our remit is to identify high quality hit/lead compounds and translate world class biology ideas into small molecule drug discovery projects, furthering the understanding of the underpinning biology and contributing to target validation.

We have funding in place to initiate up to 5 new projects per year and scout for novel biology across the UK and globally. Our work with researchers is highly collaborative. Please get in touch.